Human therapeutic antibodies.

The development of genetic engineering technologies has today advanced to the point where the generation of high-affinity human antibodies against therapeutic targets is not a major hurdle. Rather, it is the selection of target molecules in, for example, cancer therapy that poses a challenge. Targets that are not merely passive acceptors but those that signal into the cell are preferred. Recent advances in the clinical use of antibody-based therapy--such as anti-CD20 (rituximab) for the treatment of non-Hodgkin's lymphoma and anti-tumour-necrosis-factor-alpha for Crohn's disease--as well as novel antibody designs and improved understanding of the mode of action of current antibodies lend great hope to the future of this therapeutic approach.

[1]  P. T. Jones,et al.  Isolation of high affinity human antibodies directly from large synthetic repertoires. , 1994, The EMBO journal.

[2]  J. Uhr,et al.  Monoclonal antibodies as agonists: an expanded role for their use in cancer therapy. , 1994, Cancer research.

[3]  A. Lobuglio,et al.  Human immune response to monoclonal antibodies. , 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[4]  M. Feldmann,et al.  Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? , 2001, Annual review of immunology.

[5]  J. Radich,et al.  New developments in the treatment of acute myeloid leukemia. , 2000, Oncology.

[6]  L. Presta,et al.  Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets , 2000, Nature Medicine.

[7]  W. Marasco,et al.  Antibodies for targeted gene therapy: extracellular gene targeting and intracellular expression. , 1998, Advanced drug delivery reviews.

[8]  C. Borrebaeck.  Human mAbs produced by primary in-vitro immunization. , 1988, Immunology today.

[9]  T. Clackson,et al.  Making antibody fragments using phage display libraries , 1991, Nature.

[10]  J. Gerhart,et al.  Efficient construction of a large nonimmune phage antibody library: the production of high-affinity human single-chain antibodies to protein antigens. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[11]  M. Goldenberg.  Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. , 1999, Clinical therapeutics.

[12]  M. Cragg,et al.  Signaling antibodies in cancer therapy. , 1999, Current opinion in immunology.

[13]  S L Morrison,et al.  Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[14]  J. Mesirov,et al.  Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.

[15]  Meri,et al.  Rituximab (Anti‐CD20) Therapy of B‐Cell Lymphomas: Direct Complement Killing is Superior to Cellular Effector Mechanisms , 2000, Scandinavian journal of immunology.

[16]  D R Burton,et al.  A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[17]  A. Plückthun,et al.  Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides. , 2000, Journal of molecular biology.

[18]  P. T. Jones,et al.  Replacing the complementarity-determining regions in a human antibody with those from a mouse , 1986, Nature.

[19]  L. Gordon,et al.  Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. Glennie,et al.  Clinical trials of antibody therapy. , 2000, Immunology today.

[21]  César Milstein,et al.  Man-made antibodies , 1991, Nature.

[22]  E. Söderlind,et al.  Recombining germline-derived CDR sequences for creating diverse single-framework antibody libraries , 2000, Nature Biotechnology.

[23]  G. Winter,et al.  Phage antibodies: filamentous phage displaying antibody variable domains , 1990, Nature.

[24]  Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells , 2000, Cancer immunology, immunotherapy : CII.

[25]  Lutz Riechmann,et al.  Reshaping human antibodies for therapy , 1988, Nature.

[26]  M. Clark,et al.  Antibody humanization: a case of the 'Emperor's new clothes'? , 2000, Immunology today.

[27]  J. Witte,et al.  Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  S. Bernasconi,et al.  Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. , 2000, Blood.

[29]  P. Lohse,et al.  Psoralen photo-crosslinked mRNA-puromycin conjugates: a novel template for the rapid and facile preparation of mRNA-protein fusions. , 2000, Nucleic acids research.

[30]  O. Press,et al.  Therapy of B-cell lymphomas with monoclonal antibodies and radioimmunoconjugates: the Seattle experience , 2000, Annals of Hematology.

[31]  R. Levy,et al.  Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  C. White,et al.  Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. , 1999, Seminars in oncology.

[33]  M Ohlin,et al.  Does endogenous glycosylation prevent the use of mouse monoclonal antibodies as cancer therapeutics? , 1993, Immunology today.

[34]  R. Freeman,et al.  A Review of Interleukin‐2 Receptor Antagonists in Solid Organ Transplantation , 1999, Pharmacotherapy.

[35]  W. Stemmer,et al.  Evolution of a cytokine using DNA family shuffling , 1999, Nature Biotechnology.

[36]  A. Plückthun,et al.  Tailoring in vitro evolution for protein affinity or stability. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[37]  Tristan J. Vaughan,et al.  Human Antibodies with Sub-nanomolar Affinities Isolated from a Large Non-immunized Phage Display Library , 1996, Nature Biotechnology.

[38]  J. Vose,et al.  Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  A. Santoro,et al.  Ex vivo manipulation of hematopoietic stem cells for transplantation: the potential role of amifostine. , 1999, Seminars in oncology.

[40]  Andreas Plückthun,et al.  Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display , 2000, Nature Biotechnology.

[41]  C. Milstein,et al.  Continuous cultures of fused cells secreting antibody of predefined specificity , 1975, Nature.

[42]  B. Kreider.  PROfusion™: Genetically Tagged Proteins for Functional Proteomics and Beyond , 2000, Medicinal research reviews.

[43]  D R Burton,et al.  Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda. , 1989, Science.

[44]  Daniele Sblattero,et al.  Exploiting recombination in single bacteria to make large phage antibody libraries , 2000, Nature Biotechnology.